Afghanistan vs Europe (WHO region): Previously treated cases tested for RR-/MDR-TB
Afghanistan
100.0%
in 2024
Europe (WHO region)
90.0%
in 2024
Afghanistan rank
1st
Europe (WHO region) rank
2nd
Previously treated cases tested for RR-/MDR-TB over time
- Afghanistan
- Europe (WHO region)
How they compare
Afghanistan currently reports 100.0% against 90.0% in Europe (WHO region), a difference of 10.0%.
That makes Afghanistan's figure about 1.1 times Europe (WHO region)'s.
The two have swapped places 3 times across 13 shared years of data; in 2010 it was Europe (WHO region) ahead.
Afghanistan ranks 1st and Europe (WHO region) ranks 2nd of 180 countries.
Europe (WHO region) has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Afghanistan | Europe (WHO region) | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 40.7% | 60.2% | 19.5% | Europe (WHO region) |
| 2020s | 89.0% | 93.8% | 4.8% | Europe (WHO region) |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher previously treated cases tested for rr-/mdr-tb, Afghanistan or Europe (WHO region)?
- Afghanistan, at 100.0% against 90.0% in Europe (WHO region) as of 2024.
- What is the difference in previously treated cases tested for rr-/mdr-tb between Afghanistan and Europe (WHO region)?
- 10.0%, with Afghanistan ahead.
- How many years of comparable data are there for Afghanistan and Europe (WHO region)?
- 13 years are reported by both, from 2010 to 2024.
- How do Afghanistan and Europe (WHO region) rank globally for previously treated cases tested for rr-/mdr-tb?
- Afghanistan ranks 1st and Europe (WHO region) ranks 2nd of 180 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as Previously treated cases tested for RR-/MDR-TB (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.